猴痘疫苗和治疗药物全球市场规模、份额、趋势和成长分析报告（2026-2034年）

预计猴痘疫苗和治疗药物市场将从 2025 年的 1.2147 亿美元增长到 2034 年的 3.0423 亿美元，2026 年至 2034 年的复合年增长率为 10.74%。

由于全球猴痘感染疾病不断爆发，猴痘疫苗和治疗药物的全球市场备受关注。多国疫情凸显了有效疫苗和抗病毒治疗方法的迫切需求。随着各国政府和医疗机构致力于控制疫情蔓延，对预防性疫苗和治疗药物的需求也稳定成长。

製药公司和研究机构正大力投资疫苗研发和抗病毒疗法，以对抗疾病。现有的疫苗最初是为预防天花而研发的，已被证明对猴痘有效，同时人们也在寻求新的治疗方法来改善疾病管理。公共卫生措施和政府采购计画也在支持市场扩张。

随着全球对新兴感染疾病的监测和预防力度不断加强，猴痘疫苗和治疗市场预计将会成长。公众意识的提高、诊断能力的提升以及对新一代疫苗的持续研发都将促进市场发展。各国政府、医疗机构和製药公司之间的持续合作将在塑造市场未来方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球猴痘疫苗与治疗市场：依产品分类

• 市场分析、洞察与预测
• 疫苗（如 Jynneos/Imvanex、天花疫苗等）
• 药物（替可比利马特、布林西多福韦、西多福韦等）
• 牛痘免疫球蛋白（VIG）

第五章 全球猴痘疫苗与治疗市场：依性别划分

• 市场分析、洞察与预测
• 男性
• 女士
• 其他的

第六章 全球猴痘疫苗与治疗药物市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射药物

第七章 全球猴痘疫苗和治疗市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 专科诊所
• 其他的

第八章 全球猴痘疫苗和治疗市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Bavarian Noric
  • SIGA Technologies
  • Chimerix
  • Emergent
  • Gilead Sciences Inc

The Monkeypox Vaccine And Treatment Market size is expected to reach USD 304.23 Million in 2034 from USD 121.47 Million (2025) growing at a CAGR of 10.74% during 2026-2034.

The global monkeypox vaccine and treatment market has gained considerable attention due to the increasing incidence of monkeypox infections across various regions. The outbreak of the disease in several countries has highlighted the need for effective vaccines and antiviral treatments. As governments and healthcare organizations focus on controlling outbreaks, the demand for preventive vaccines and therapeutic drugs is increasing steadily.

Pharmaceutical companies and research institutions are investing heavily in vaccine development and antiviral therapies to address the disease. Existing vaccines originally developed for smallpox have shown effectiveness against monkeypox, while new treatments are being explored to improve disease management. Public health initiatives and government procurement programs are also supporting the expansion of the market.

In the future, the monkeypox vaccine and treatment market is expected to grow as global surveillance and preparedness for emerging infectious diseases increase. Rising awareness, improved diagnostic capabilities, and ongoing research into next-generation vaccines will contribute to market development. Continued collaboration between governments, healthcare organizations, and pharmaceutical companies will play a key role in shaping the market's future.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others)
• Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others)
• Vaccinia Immune Globulin (Vig)

By Gender

• Male
• Female
• Others

By Route Of Administration

• Oral
• Injectable
• By-End-Use
• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Bavarian Noric, SIGA Technologies, Chimerix, Emergent, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Immune Globulin (Vig) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gender
• 5.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY BY-END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast By-end-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Gender
  • 8.2.3 By Route Of Administration
  • 8.2.4 By By-end-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Gender
  • 8.3.3 By Route Of Administration
  • 8.3.4 By By-end-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Gender
  • 8.4.3 By Route Of Administration
  • 8.4.4 By By-end-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Gender
  • 8.5.3 By Route Of Administration
  • 8.5.4 By By-end-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Gender
  • 8.6.3 By Route Of Administration
  • 8.6.4 By By-end-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONKEYPOX VACCINE AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bavarian Noric
  • 10.2.2 SIGA Technologies
  • 10.2.3 Chimerix
  • 10.2.4 Emergent
  • 10.2.5 Gilead Sciences Inc